Investigation Report on Chinese Atorvastatin Market, 2018-2022


Description
The number of patients with hyperlipidemia is increasing in China with the life style change resulting from economic development and the rise of residents' income. It is estimated that there are over 100 million patients with hyperlipidemia and 160 million patients with dyslipidemia in China. And the figures are increasing every year. 
Atorvastatin is a common drug that lowers blood cholesterol levels. It was developed by Pfizer in the trade name of Lipitor. It has been proved that Atorvastatin is safe and can decrease major cardiovascular events for patients with coronary heart disease, ischemic stroke, diabetes and high-risk patients with cardiovascular diseases such as hypertension. By the end of 2017, the global sales of Lipitor had exceeded USD 150 billion, creating a miracle in global drug sales. 
According to CRI, Atorvastatin has been growing rapidly since it entered China, with its sales revenue increasing from less than CNY 200 million in 2005 to more than CNY 2.21 billion in 2017. There is a high demand for Atorvastatin in China. In addition to Pfizer's brand-name drug Lipitor, generic drugs of Beijing Jialin Pharmaceutical Co., Ltd., China Meheco Topfond Pharma Co., Ltd., Zhejiang Neo-Dankong Pharmaceutical Co., Ltd., Guangdong Baike Pharmaceutical Co., Ltd., etc. are also sold on the market. Pfizer captured the largest market share by sales value. Its market share exceeded 70% with a sales value over CNY 1.6 billion in 2017. 
It is estimated that the number of patients with hyperlipidemia will continue to grow in China in the next few years, which will lead to a rising demand for Atorvastatin. 

Topics Covered:
- Development environment of Atorvastatin in China
- Sales of Atorvastatin in China
- Prices of Atorvastatin in China
- Major Atorvastatin manufacturers in China
- Market share of Atorvastatin by dosage form in China
- Prospect of Chinese Atorvastatin Market, 2018-2022
Table of Contents
1 Relevant Concepts of Atorvastatin
1.1 Indications for Atorvastatin
1.2 Development History of Atorvastatin in China
1.3 Patents and Government Approval on Atorvastatin in China

2 Sales of Atorvastatin in China, 2013-2017
2.1 Sales Value of Atorvastatin
2.1.1 Overall Sales Value
2.1.2 Sales Value in Parts of China
2.2 Sales Volume of Atorvastatin
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Atorvastatin by Dosage Form in China, 2013-2017
2.3.1 Tablets
2.3.2 Capsules

3 Analysis on Major Atorvastatin Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Atorvastatin Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Pfizer
3.2.1 Enterprise Profile
3.2.2 Sales of Pfizer's Atorvastatin in China
3.3 Beijing Jialin Pharmaceutical Co., Ltd. 
3.3.1 Enterprise Profile
3.3.2 Sales of Beijing Jialin Pharmaceutical Co., Ltd.'s Atorvastatin in China
3.4 China Meheco Topfond Pharma Co., Ltd. 
3.4.1 Enterprise Profile
3.4.2 Sales of China Meheco Topfond Pharma Co., Ltd.'s Atorvastatin in China
3.5 Zhejiang Neo-Dankong Pharmaceutical Co., Ltd. 
3.5.1 Enterprise Profile
3.5.2 Sales of Zhejiang Neo-Dankong Pharmaceutical Co., Ltd.'s Atorvastatin in China
3.6 Guangdong Baike Pharmaceutical Co., Ltd. 
3.6.1 Enterprise Profile
3.6.2 Sales of Guangdong Baike Pharmaceutical Co., Ltd.'s Atorvastatin in China

4 Prices of Different Manufacturers' Atorvastatin in China, 2017-2018
4.1 Pfizer (Trade Name: Lipitor)
4.2 Beijing Jialin Pharmaceutical Co., Ltd. (Trade Name: Ale)
4.3 China Meheco Topfond Pharma Co., Ltd. (Trade Name: Youjia)
4.4 Zhejiang Neo-Dankong Pharmaceutical Co., Ltd. (Trade Name: Youliping)
4.5 Guangdong Baike Pharmaceutical Co., Ltd. (Trade Name: Jingshu)

5 Prospect of Chinese Atorvastatin Market, 2018-2022
5.1 Factors Influencing Development
5.1.1 Driving Forces and Market Opportunities
5.1.2 Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

Selected Charts
Chart Government Approval of Atorvastatin in China
Chart Sales Value of Atorvastatin in China, 2013-2017
Chart Sales Value of Atorvastatin in Parts of China, 2013-2017
Chart Sales Volume of Atorvastatin in China, 2013-2017
Chart Market Share of Top 5 Atorvastatin Manufacturers by Sales Value, 2013-2017
Chart Sales Value and Market Share of Pfizer's Atorvastatin in China, 2013-2017
Chart Sales Value and Market Share of Beijing Jialin Pharmaceutical Co., Ltd.'s Atorvastatin in China, 2013-2017
Chart Sales Value and Market Share of China Meheco Topfond Pharma Co., Ltd.'s Atorvastatin in China, 2013-2017
Chart Sales Value and Market Share of Atorvastatin Tablets in China, 2013-2017
Chart Sales Value and Market Share of Atorvastatin Capsules in China, 2013-2017
Chart Prices of Beijing Jialin Pharmaceutical Co., Ltd.'s Atorvastatin in Parts of China, 2017-2018
Chart Prices of China Meheco Topfond Pharma Co., Ltd.'s Atorvastatin in Parts of China, 2017-2018
Chart Forecast on Sales Volume of Atorvastatin in China, 2018-2022


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by China Research and Intelligence

Investigation Report on China's Finasteride Market, 2019-2023

Description The prostate is a male-specific gonadal organ. Benign prostatic hyperplasia (BPH) is the most common benign disease among the causes of urination disorder in middle-aged and elderly men. Epidemiologically, the incidence of BPH increases w...

Investigation Report on China's Prothrombin Complex Concentrate (PCC) Market, 2019-2023

Description Hemophilia is an X-linked recessive hemorrhagic disease. It is classified into hemophilia A, a deficiency in clotting factor VIII and hemophilia B, a deficiency in clotting factor IX. Both hemophilia A and hemophilia B are caused by gene ...

Investigation Report on China's Recombinant Human Thrombopoietin Market, 2019-2023

Description In recent years, the incidence of thrombopenia in China keeps increasing. Thrombopenia is often seen in hematologic diseases such as primary immune thrombopenia, leukemia and aplastic anemia as well as in connective tissue diseases, liver...

Investigation Report on China's Pegaspargase Market, 2019-2023

Description According to the data released by China?s National Health Commission in Oct. 2018, the incidence of childhood leukemia in Chinese children under 15 is about 4/100,000 to 5/100,000, and the number of childhood leukemia patients under 18 ol...

Investigation Report on China's Basiliximab Market, 2019-2023

Description In China, 10.80% or about 150 million people have chronic kidney disease, and over 3 million of them have end-stage renal disease, i.e. uremia. According to CRI, the incidence of chronic kidney disease in China stays at a high level in re...

New Pharmaceuticals and Healthcare Reports

Publisher: China Research and Intelligence